Finally, our findings suggest that targeting the canonical NF-κB pathway is a potential therapeutic strategy for stabilizing dendritic structures and maintaining corticospinal connectivity in patients with ALS/FTD. The gene discussed is NFKB1; the disease is amyotrophic lateral sclerosis.